Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
J Antimicrob Chemother ; 79(6): 1407-1412, 2024 Jun 03.
Artículo en Inglés | MEDLINE | ID: mdl-38656566

RESUMEN

BACKGROUND: Invasive candidiasis is still recognized as a major cause of morbidity and mortality. To support clinicians in the optimal use of antifungals for the treatment of invasive candidiasis, a computerized decision support system (CDSS) was developed based on institutional guidelines. OBJECTIVES: To evaluate the correlation of this newly developed CDSS with clinical practices, we set-up a retrospective multicentre cohort study with the aim of providing the concordance rate between the CDSS recommendation and the medical prescription (NCT05656157). PATIENTS AND METHODS: Adult patients who received caspofungin or fluconazole for the treatment of an invasive candidiasis were included. The analysis of factors associated with concordance was performed using mixed logistic regression models with department as a random effect. RESULTS: From March to November 2022, 190 patients were included from three centres and eight departments: 70 patients from centre A, 84 from centre B and 36 from centre C. Overall, 100 patients received caspofungin and 90 received fluconazole, mostly (59%; 112/190) for empirical/pre-emptive treatment. The overall percentage of concordance between the CDSS and medical prescriptions was 91% (173/190) (confidence interval 95%: 82%-96%). No significant difference in concordance was observed considering the centres (P > 0.99), the department of inclusion (P = 0.968), the antifungal treatment (P = 0.656) or the indication of treatment (P = 0.997). In most cases of discordance (n = 13/17, 76%), the CDSS recommended fluconazole whereas caspofungin was prescribed. The clinical usability evaluated by five clinicians was satisfactory. CONCLUSIONS: Our results demonstrated the high correlation between current antifungal clinical practice and this user-friendly and institutional guidelines-based CDSS.


Asunto(s)
Antifúngicos , Candidiasis Invasiva , Caspofungina , Sistemas de Apoyo a Decisiones Clínicas , Fluconazol , Humanos , Estudios Retrospectivos , Antifúngicos/uso terapéutico , Antifúngicos/administración & dosificación , Masculino , Femenino , Persona de Mediana Edad , Fluconazol/uso terapéutico , Fluconazol/administración & dosificación , Anciano , Candidiasis Invasiva/tratamiento farmacológico , Caspofungina/uso terapéutico , Caspofungina/administración & dosificación , Adulto , Anciano de 80 o más Años , Pautas de la Práctica en Medicina/estadística & datos numéricos
2.
Clin Infect Dis ; 75(1): 88-97, 2022 08 24.
Artículo en Inglés | MEDLINE | ID: mdl-34596213

RESUMEN

BACKGROUND: Nocardiosis is rare after hematopoietic cell transplantation (HCT). Little is known regarding its presentation, management, and outcome in this population. METHODS: This retrospective international study reviewed nocardiosis episodes in HCT recipients (1/1/2000-31/12/2018; 135 transplant centers; 33 countries) and described their clinical, microbiological, radiological, and outcome characteristics. RESULTS: We identified 81 nocardiosis episodes in 74 allo- and 7 auto-HCT recipients. Nocardiosis occurred a median of 8 (IQR: 4-18) months post-HCT. The most frequently involved organs were lungs (70/81; 86%) and brain (30/81; 37%); 29 (36%) patients were afebrile; 46/81 (57%) had disseminated infections. The most common lung imaging findings were consolidations (33/68; 49%) or nodules (32/68; 47%); brain imaging findings were multiple brain abscesses (19/30; 63%). Ten of 30 (33%) patients with brain involvement lacked neurological symptoms. Fourteen of 48 (29%) patients were bacteremic. Nocardia farcinica was the most common among molecularly identified species (27%; 12/44). Highest susceptibility rates were reported to linezolid (45/45; 100%), amikacin (56/57; 98%), trimethoprim-sulfamethoxazole (57/63; 90%), and imipenem (49/57; 86%). One-year and last follow-up (IQR: 4-42.5 months) all-cause mortality were 40% (32/81) and 52% (42/81), respectively. In the multivariable analysis, underlying disease not in complete remission (HR: 2.81; 95% CI: 1.32-5.95) and prior bacterial infection (HR: 3.42; 95% CI: 1.62-7.22) were associated with higher 1-year all-cause mortality. CONCLUSIONS: Nocardiosis is a late post-HCT infection usually manifesting as a pulmonary disease with frequent dissemination, brain infection, and bacteremia. Brain imaging should be performed in HCT recipients with nocardiosis regardless of neurological symptoms. Overall mortality is high.


Asunto(s)
Bacteriemia , Enfermedades Transmisibles , Trasplante de Células Madre Hematopoyéticas , Enfermedades Pulmonares , Nocardiosis , Nocardia , Antibacterianos/uso terapéutico , Bacteriemia/tratamiento farmacológico , Médula Ósea , Enfermedades Transmisibles/tratamiento farmacológico , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Humanos , Enfermedades Pulmonares/microbiología , Nocardiosis/diagnóstico , Nocardiosis/tratamiento farmacológico , Nocardiosis/epidemiología , Estudios Retrospectivos , Receptores de Trasplantes
3.
Clin Infect Dis ; 71(7): e186-e190, 2020 10 23.
Artículo en Inglés | MEDLINE | ID: mdl-31916572

RESUMEN

We provide the first description of a series of 9 severe gynecological infections (mastitis and pelvic cellulitis) occurring in the French national cohort of women with STAT3 deficiency. Each episode had unique features in terms of clinical presentation, microbial documentation, location, treatment duration, and related persistent esthetic damage.


Asunto(s)
Mastitis/genética , Parametritis/genética , Factor de Transcripción STAT3 , Estudios de Cohortes , Femenino , Humanos , Mutación , Factor de Transcripción STAT3/deficiencia , Factor de Transcripción STAT3/genética , Adulto Joven
4.
Artículo en Inglés | MEDLINE | ID: mdl-31405852

RESUMEN

We report the cases of a 39-year-old woman with chronic lymphocytic leukemia and a 21-year-old man with chronic granulomatous disease treated for cerebral aspergillosis. The patients required radical surgery for infection progression despite adequate isavuconazole plasma concentration or neurological complication. We thus decided to measure the brain isavuconazole concentration. These results suggest that the concentrations of isavuconazole obtained in the infected brain tissue clearly differ from those obtained in the normal brain tissue and the cerebrospinal fluid.


Asunto(s)
Encéfalo/microbiología , Enfermedad Granulomatosa Crónica/tratamiento farmacológico , Nitrilos/uso terapéutico , Piridinas/uso terapéutico , Triazoles/uso terapéutico , Adulto , Aspergilosis/tratamiento farmacológico , Aspergilosis/microbiología , Aspergillus fumigatus/efectos de los fármacos , Aspergillus fumigatus/patogenicidad , Líquido Cefalorraquídeo , Femenino , Enfermedad Granulomatosa Crónica/microbiología , Humanos , Imagen por Resonancia Magnética , Adulto Joven
5.
Med Mycol ; 57(Supplement_2): S94-S103, 2019 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-30816963

RESUMEN

Invasive aspergillosis (IA) incidence is increasing in several countries like France, and numerous cases are indeed missed and still only diagnosed at autopsy as evidenced by recently published data. Such missed diagnoses are obviously encountered when appropriate diagnostic tools are not available especially in low resource areas or when biologists have not been trained enough in medical mycology (i.e., microscopic examination and culture in most of those areas). Besides logistical issues, which are indeed critical, IA may not be recognized because clinicians failed to consider that risk factors are evolving with the IA burden now observed among patients with chronic lymphoid malignancies or receiving new biotherapies, with diabetes mellitus or liver cirrhosis and/or acute alcoholic hepatitis, with patients from the intensive care unit (ICU) and among patients with some predisposing primary immune deficiencies now reaching the adult's age. This is also the case for human immunodeficiency virus (HIV)-infected patients who failed to meet the classical definitions of IA. From the radiology perspective, new entities of IA have also emerged which absolutely need to be recognized especially bronchial-based-IA among allogeneic stem cell transplant recipients. Finally, from the laboratory side, contribution and limits of indirect blood biomarkers should be integrated to the clinical life in order not to miss IA cases. To conclude, several diagnostic tools should be combined and a constant dialog between laboratory and clinics is crucial to appropriately diagnose IA.


Asunto(s)
Pruebas Diagnósticas de Rutina/métodos , Huésped Inmunocomprometido , Aspergilosis Pulmonar Invasiva/diagnóstico , Aspergilosis Pulmonar Invasiva/epidemiología , Francia/epidemiología , Humanos , Incidencia , Factores de Riesgo
6.
Rev Med Suisse ; 13(558): 815-819, 2017 Apr 12.
Artículo en Francés | MEDLINE | ID: mdl-28727331

RESUMEN

Toxocariasis is a zoonotic disease that occurs when humans are infected by the parasites Toxocara canis or Toxocara cati. Toxocariasis is highly prevalent in tropical areas, but can also be found in industrialized countries, particularly in rural areas. Clinical presentation can range from asymptomatic infection to more severe disease. Diagnosis of toxocariasis is based on suggestive clinical findings, eosinophilia and a positive serological testing. Albendazole represents the first-line treatment, associated with corticosteroids in case of severe disease. Here we describe three clinical cases of toxocariasis in order to illustrate the clinical presentation, diagnosis and treatment of this unrecognized disease.


La toxocarose est une zoonose liée à l'infection de l'homme par Toxocara canis et Toxocara cati. Sa prévalence est élevée dans les zones tropicales, mais également dans les pays industrialisés, notamment dans les zones rurales. La plupart des formes sont asymptomatiques, se révélant par la présence d'une éosinophilie. Une dissémination, syndrome de larva migrans viscérale, et une atteinte oculaire, syndrome de larva migrans oculaire, sont les deux principaux syndromes. Le diagnostic de la toxocarose repose sur la présence d'une symptomatologie compatible, d'une éosinophilie et d'une sérologie positive. Le traitement de choix est l'albendazole, associé aux corticostéroïdes en cas d'atteinte sévère. Nous présentons trois cas de toxocarose, afin d'illustrer la présentation, le diagnostic et la prise en charge de cette infection méconnue.


Asunto(s)
Enfermedades Desatendidas/diagnóstico , Toxocariasis/diagnóstico , Zoonosis/diagnóstico , Corticoesteroides/uso terapéutico , Adulto , Anciano , Albendazol/uso terapéutico , Animales , Eosinofilia/diagnóstico , Eosinofilia/parasitología , Femenino , Humanos , Persona de Mediana Edad , Enfermedades Desatendidas/tratamiento farmacológico , Enfermedades Desatendidas/epidemiología , Prevalencia , Pruebas Serológicas , Suiza/epidemiología , Toxocara/aislamiento & purificación , Toxocariasis/tratamiento farmacológico , Toxocariasis/epidemiología , Zoonosis/tratamiento farmacológico , Zoonosis/parasitología
7.
J Infect ; 88(6): 106162, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38663756

RESUMEN

OBJECTIVES: Nocardiosis is a rare but life-threatening infection after hematopoietic cell transplantation (HCT). We aimed at identifying risk factors for nocardiosis after allogeneic HCT and clarifying the effect of trimethoprim-sulfamethoxazole prophylaxis on its occurrence. METHODS: We performed a retrospective multicenter case-control study of patients diagnosed with nocardiosis after allogeneic HCT between January 2000 and December 2018. For each case, two controls were matched by center, transplant date, and age group. Multivariable analysis was conducted using conditional logistic regression to identify potential risk factors for nocardiosis. Kaplan-Meier survival curves of cases and controls were compared using log-rank tests. RESULTS: Sixty-four cases and 128 controls were included. Nocardiosis occurred at a median of 9 months after allogeneic HCT (interquartile range: 5-18). After adjustment for potential confounders in a multivariable model, Nocardia infection was associated with tacrolimus use (adjusted odds ratio [aOR] 9.9, 95 % confidence interval [95 % CI]: 1.6-62.7), lymphocyte count < 500/µL (aOR 8.9, 95 % CI: 2.3-34.7), male sex (aOR 8.1, 95 % CI: 2.1-31.5), recent use of systemic corticosteroids (aOR 7.9, 95 % CI: 2.2-28.2), and recent CMV infection (aOR 4.3, 95 % CI: 1.2-15.9). Conversely, use of trimethoprim-sulfamethoxazole prophylaxis was associated with a significantly decreased risk of nocardiosis (aOR 0.2, 95 % CI: 0.1-0.8). HCT recipients who developed nocardiosis had a significantly decreased survival, as compared with controls (12-month survival: 58 % and 90 %, respectively; p < 0.0001). CONCLUSIONS: We identified six factors independently associated with the occurrence of nocardiosis among allogeneic HCT recipients. In particular, trimethoprim-sulfamethoxazole prophylaxis was found to protect against nocardiosis.


Asunto(s)
Trasplante de Células Madre Hematopoyéticas , Nocardiosis , Combinación Trimetoprim y Sulfametoxazol , Humanos , Nocardiosis/epidemiología , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Masculino , Femenino , Estudios de Casos y Controles , Factores de Riesgo , Persona de Mediana Edad , Estudios Retrospectivos , Adulto , Combinación Trimetoprim y Sulfametoxazol/uso terapéutico , Trasplante Homólogo/efectos adversos , Anciano , Receptores de Trasplantes/estadística & datos numéricos , Nocardia/aislamiento & purificación , Profilaxis Antibiótica
9.
Transplant Direct ; 7(3): e675, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-34113715

RESUMEN

We sought to determine whether invasive aspergillosis (IA) during the first year after lung transplantation increased the risk of chronic lung allograft dysfunction (CLAD). METHODS: We retrospectively reviewed the records of 191 patients who underwent lung transplantation at our institution between January 2013 and December 2017. Screening for Aspergillus was with bronchial aspirates, bronchoalveolar lavage if indicated or during surveillance bronchoscopy, radiography, and computed tomography. We used Fine and Gray multivariable regression to identify potential risk factors for CLAD. RESULTS: During the first posttransplant year, 72 patients had at least 1 deep-airway sample positive for Aspergillus; 63 were classified as having IA and were included in the study. Median number of endoscopies per patient during the first year was 9 (range, 1-44). Median time from transplantation to first Aspergillus-positive sample was 121 d. Bronchial aspirate samples and bronchoalveolar lavage fluid were positive in 71 and 44 patients, respectively. Aspergillus fumigatus (n = 36, 50%) predominated; bacterial samples were also positive in 22 (31%) patients. IA within 4 mo after transplantation was independently associated with CLAD development (subdistribution hazard ratio, 3.75; 95% confidence interval [CI], 1.61-8.73; P < 0.01) by regression analysis. Survival at 3 and 5 y conditional on 1-y CLAD-free survival was 37% (95% CI, 24%-58%), and 24% (95% CI, 11%-52%) in the IA <4 mo group compared to 65% (95% CI, 57%-73%) and 54% (95% CI, 43%-66%) in the non-IA group and to 69% (95% CI, 58%-83%) and 54% (95% CI, 35%-82%) in the IA ≥4 mo group, respectively (P < 0.01, logrank test). CONCLUSIONS: Our evaluation of de novo IA showed that this infection was most strongly associated with CLAD when found within 4 mo after transplantation.

10.
J Med Microbiol ; 69(6): 844-849, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-32459615

RESUMEN

Introduction. Signal transducer and activator of transcription 3 (STAT3) deficiency is a rare primary immunodeficiency associated with increased susceptibility to bacterial and fungal infections, notably pulmonary aspergillosis.Aim. We describe the emergence of azole-resistant Aspergillus fumigatus infections in STAT3-deficient patients.Methodology. During a retrospective study of 13 pulmonary aspergillosis cases in STAT3-deficient patients conducted in France, we identified patients infected with azole-resistant A. fumigatus isolates.Results. Two out of the 13 STAT3-deficient patients with aspergillosis had azole-resistant A. fumigatus infection, indicating an unexpectedly high prevalence of resistance. The first patient with STAT3 deficiency presented several flares of allergic bronchopulmonary aspergillosis-like episodes. He was chronically infected with two azole-resistant A. fumigatus isolates (TR34/L98). Despite prolonged antifungal treatment, including caspofungin and amphotericin B, the patient was not able to clear the azole-resistant A. fumigatus. The second patient had chronic cavitary pulmonary aspergillosis (CCPA). The A. fumigatus isolate was initially azole susceptible but harboured three F46Y, M172V and E427K point mutations. Despite prolonged antifungal therapies, lesions worsened and the isolate became resistant to all azoles. Surgery and caspofungin treatments were then required to cure CCPA. Resistance was probably acquired from the environment (TR34/L98) in the first case whereas resistance developed under antifungal treatments in the second case. These infections required long-term antifungal treatments and surgery.Conclusions. The emergence of azole-resistant A. fumigatus infections in STAT3-deficiency dramatically impacts both curative and prophylactic antifungal strategies. Physicians following patients with primary immune-deficiencies should be aware of this emerging problem as it complicates management of the patient.


Asunto(s)
Antifúngicos/uso terapéutico , Aspergillus fumigatus/efectos de los fármacos , Azoles/uso terapéutico , Farmacorresistencia Fúngica/efectos de los fármacos , Aspergilosis Pulmonar/tratamiento farmacológico , Aspergilosis Pulmonar/genética , Factor de Transcripción STAT3/deficiencia , Adulto , Anfotericina B/uso terapéutico , Caspofungina/uso terapéutico , Niño , Enfermedades Transmisibles/tratamiento farmacológico , Enfermedades Transmisibles/genética , Enfermedades Transmisibles/microbiología , Farmacorresistencia Fúngica/genética , Francia , Proteínas Fúngicas/genética , Genotipo , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Estudios Retrospectivos , Adulto Joven
11.
Front Immunol ; 11: 38, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32047500

RESUMEN

In humans, loss-of-function mutation in the Signal Transducer and Activator of Transcription 3 (STAT3) gene is frequently associated with susceptibility to bacterial as well as fungal infections including aspergillosis, although its pathogenesis remains largely unknown. In the present study, we investigated the immune responses obtained after stimulation with Aspergillus fumigatus in STAT3-deficient patients. A. fumigatus conidial killing efficiencies of both monocytes and neutrophils isolated from whole blood samples of STAT3-deficient patients were not different compared to those of healthy controls. After stimulation with A. fumigatus conidia, lower concentrations of adaptive cytokines (IFN-γ, IL-17 and IL-22) were secreted by peripheral blood mononuclear cells from STAT3-deficient patients compared to those from healthy controls. Moreover, the frequency of IFN-γ and IL-17 producing CD4+ T cells was lower in STAT3-deficient patients vs. healthy controls. Among the STAT3-deficient patients, those with aspergillosis showed further lower secretion of IFN-γ upon stimulation of their PBMCs with A. fumigatus conidia compared to the patients without aspergillosis. Together, our study indicated that STAT3-deficiency leads to a defective adaptive immune response against A. fumigatus infection, particularly with a lower IFN-γ and IL-17 responses in those with aspergillosis, suggesting potential therapeutic benefit of recombinant IFN-γ in STAT3-deficient patients with aspergillosis.


Asunto(s)
Aspergilosis/sangre , Aspergilosis/inmunología , Aspergillus fumigatus/inmunología , Interferón gamma/metabolismo , Activación de Linfocitos/inmunología , Factor de Transcripción STAT3/deficiencia , Células Th17/inmunología , Adulto , Aspergilosis/microbiología , Estudios de Casos y Controles , Células Cultivadas , Femenino , Humanos , Inmunoglobulina E/sangre , Inmunoglobulina E/inmunología , Inmunoglobulina G/sangre , Inmunoglobulina G/inmunología , Interleucina-17/metabolismo , Síndrome de Job/inmunología , Mutación con Pérdida de Función , Masculino , Persona de Mediana Edad , Monocitos/inmunología , Neutrófilos/inmunología , Factor de Transcripción STAT3/genética , Adulto Joven
12.
PLoS Negl Trop Dis ; 14(12): e0008931, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-33326423

RESUMEN

BACKGROUND: Despite direct-acting antivirals (DAA), aims to "eradicate" viral hepatitis by 2030 remain unlikely. In Nepal, an expert consortium was established to treat HCV through Nepal earthquakes aftermath offering a model for HCV treatment expansion in a resource-poor setting. METHODOLOGY/PRINCIPAL FINDINGS: In 2015, we established a network of hepatologists, laboratory experts, and community-based leaders at 6 Opioid Substitution Treatment (OST) sites from 4 cities in Nepal screening 838 patients for a treatment cohort of 600 individuals with HCV infection and past or current drug use. During phase 1, patients were treated with interferon-based regimens (n = 46). During phase 2, 135 patients with optimal predictors (HIV controlled, without cirrhosis, low baseline HCV viral load) were treated with DAA-based regimens. During phase 3, IFN-free DAA treatment was expanded, regardless of HCV disease severity, HIV viremia or drug use. Sustained virologic response (SVR) was assessed at 12 weeks. Median age was 37 years and 95.5% were males. HCV genotype was 3 (53.2%) or 1a (40.7%) and 32% had cirrhosis; 42.5% were HIV-HCV coinfected. The intention-to-treat (ITT) SVR rates in phase 2 and 3 were 97% and 81%, respectively. The overall per-protocol and ITT SVR rates were 97% and 85%, respectively. By multivariable analysis, treatment at the Kathmandu site was protective and substance use, treatment during phase 3 were associated with failure to achieve SVR. CONCLUSIONS/SIGNIFICANCE: Very high SVR rates may be achieved in a difficult-to-treat, low-income population whatever the patient's profile and disease severity. The excellent treatment outcomes observed in this real-life community study should prompt further HCV treatment initiatives in Nepal.


Asunto(s)
Antivirales/uso terapéutico , Infecciones por VIH/complicaciones , Hepacivirus/efectos de los fármacos , Hepatitis C/tratamiento farmacológico , Interferones/uso terapéutico , Cirrosis Hepática/complicaciones , Adulto , Coinfección , Quimioterapia Combinada , Femenino , Hepatitis C/complicaciones , Hepatitis C/virología , Humanos , Cirrosis Hepática/virología , Masculino , Nepal , Respuesta Virológica Sostenida , Resultado del Tratamiento
13.
J Allergy Clin Immunol Pract ; 7(6): 1986-1995.e3, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30878710

RESUMEN

BACKGROUND: Autosomal-dominant signal transducer and activator of transcription 3 (STAT3) deficiency predisposes to recurrent bacterial pneumonia, complicated by bronchiectasis and cavitations. Aspergillosis is a major cause of morbidity in these patients. However, its diagnosis, classification, and treatment are challenging. OBJECTIVE: We aimed to assess the prevalence and describe the clinical, mycological, and radiological presentation and related therapy and outcome of Aspergillus infections of the respiratory tract in the STAT3-deficient patients of the National French cohort. METHODS: We performed a retrospective study of all pulmonary aspergillosis cases in STAT3-deficient patients (n = 74). Clinical and mycological data were collected up to October 2015 and imaging was centralized. RESULTS: Twenty-one episodes of pulmonary aspergillosis in 13 (17.5%) STAT3-deficient patients were identified. The median age at first episode was 13 years (interquartile range, 10-26 years). Ninety percent of patients had previous bronchiectasis or cavitations. Infections were classified as follows: 5 single aspergilloma, 9 chronic cavity pulmonary aspergillosis, 5 allergic bronchopulmonary aspergillosis-like disease, and 2 mixed forms of concomitant allergic bronchopulmonary aspergillosis-like disease and chronic cavity pulmonary aspergillosis. No invasive aspergillosis cases were identified. Aspergillus species were isolated in 71% of episodes and anti-Aspergillus antibodies in 93%. Eleven episodes were breakthrough infections. Antifungal treatment was prolonged, with a median of 13 months, and 6 patients (7 episodes) required surgery, with a high rate of postsurgical complications. One patient died and 6 had a relapse. CONCLUSIONS: Chronic and allergic forms of aspergillosis occurred in 17.5% of STAT3-deficient patients, mostly in lung cavities. Almost half had recurrences, despite prolonged antifungal treatment and/or surgery.


Asunto(s)
Síndrome de Job , Aspergilosis Pulmonar , Factor de Transcripción STAT3/deficiencia , Adolescente , Adulto , Antifúngicos/uso terapéutico , Niño , Femenino , Francia/epidemiología , Humanos , Síndrome de Job/diagnóstico por imagen , Síndrome de Job/tratamiento farmacológico , Síndrome de Job/epidemiología , Masculino , Aspergilosis Pulmonar/diagnóstico por imagen , Aspergilosis Pulmonar/tratamiento farmacológico , Aspergilosis Pulmonar/epidemiología , Estudios Retrospectivos , Tomografía Computarizada por Rayos X , Adulto Joven
14.
Medicine (Baltimore) ; 96(49): e8846, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-29245251

RESUMEN

Sarcoidosis is associated with cell-mediated immunodeficiency and treatment of symptomatic sarcoidosis usually includes systemic immunosuppressants. Data relative to incidence, prognosis factors, and outcome of infections are scarce.Retrospective cohort study of 585 patients with biopsy proven sarcoidosis in a tertiary referral specialist clinic, with a nested case-control analysis. Twenty nine patients (4.9%) with severe infections were compared to 116 controls subjects with sarcoidosis, matched according to their gender, ethnicity, age at diagnosis, and treatment with corticosteroids.After a median follow-up of 8 years [range; 1-46], 38 severe infections [mycobacterial infections (n = 14), fungal infections (n = 10), bacterial (n = 8), viral (n = 3) and parasitic (n = 1)] were observed in 30 patients. The incidence of severe infections was 0.71% persons-year (CI 95% 0.5-0.98) and 0.43% persons-year (CI 95% 0.27-0.66). Patients with severe infection were more frequently of male gender (60% vs 46%) and were more likely treated by ≥ 3 immunosuppressive agents (OR = 3.8, IC 95% [1.5-9.64], P = .005) and by cyclophosphamide (OR = 5.55, IC 95% [1.9-16.1], P = .002), and with neurological (OR = 3.36 CI 95% [1.37-8.25], P = .008), or cardiac (OR = 2.65 CI 95% [1.09-6.43], P = .031) involvement of the sarcoidosis, compared to the controls. Two patients died within the 6 months following infection, due to progressive multifocal leucoencephalopathy (n = 1), and of peritonitis (n = 1).Severe infections are observed in 5.1% of our patients with sarcoidosis after a median follow-up of 8 years. Risk factors for severe infections included neurological or cardiac involvement of sarcoidosis, the use of immunosuppressive agents and mainly cyclophosphamide.


Asunto(s)
Inmunosupresores/efectos adversos , Infecciones Oportunistas/epidemiología , Sarcoidosis/tratamiento farmacológico , Corticoesteroides/efectos adversos , Adulto , Estudios de Casos y Controles , Ciclofosfamida/efectos adversos , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Infecciones Oportunistas/microbiología , Estudios Retrospectivos , Factores de Riesgo , Sarcoidosis/microbiología , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA